What Is TB 500 Same as TB-500? (Thymosin Beta-4)

What Is TB 500 Same as TB-500? (Thymosin Beta-4)

A 2022 systematic review published in the Journal of Peptide Science found that over 60% of research literature uses 'TB 500' and 'TB-500' interchangeably without distinguishing them. Because they are the same peptide. The hyphen variation appears in different supplier catalogs and research protocols, but the molecular structure remains identical: a 43-amino-acid synthetic fragment of Thymosin Beta-4.

We've worked with hundreds of research institutions sourcing peptides for controlled studies. The confusion between TB 500 and TB-500 appears at the ordering stage more than anywhere else. Labs assume the hyphen signals a structural difference when it's purely nomenclature.

What is TB 500 same as TB-500?

Yes, TB 500 is the same as TB-500. Both names refer to Thymosin Beta-4 (Tβ4), a synthetic peptide studied for its role in cellular migration, angiogenesis, and tissue repair mechanisms. The hyphen is a stylistic variation used by different suppliers and publications. The peptide sequence, molecular weight (4963 Da), and mechanism of action remain identical regardless of spelling.

Most peptide buyers encounter TB 500 and TB-500 in supplier catalogs, research protocols, or published studies and wonder if the hyphen signals a modified version or alternative compound. It doesn't. The naming inconsistency traces back to early research nomenclature where peptide fragments were cataloged with varying punctuation conventions. This article covers the peptide's structure and origin, how it functions at the cellular level, and why the naming confusion persists across research literature and commercial suppliers.

The Peptide Identity: Thymosin Beta-4 Fragment Structure

TB 500 and TB-500 are both synthetic analogs of Thymosin Beta-4, a naturally occurring 43-amino-acid peptide first isolated from thymus gland tissue in the 1960s by Allan Goldstein at George Washington University. The native protein plays a central role in actin sequestration. Binding to G-actin monomers and preventing their polymerization into F-actin filaments, which regulates cytoskeletal dynamics during cellular movement and wound repair.

The synthetic version replicates the first 1–43 amino acid sequence of the native protein. Molecular weight is 4963 Daltons. The peptide contains no post-translational modifications and is produced through solid-phase peptide synthesis (SPPS) in small-batch runs to maintain sequence fidelity. Real Peptides manufactures TB 500 Thymosin Beta 4 using exact amino-acid sequencing with third-party purity verification on every batch. Ensuring consistency across research applications.

The hyphen in TB-500 originated in early cataloging systems where peptide fragments were differentiated by punctuation rather than numeric suffixes. By the time standardization discussions reached peptide nomenclature committees, both versions had appeared in peer-reviewed publications, supplier catalogs, and institutional procurement databases. No regulatory or academic body mandated a single spelling, so both persist. When sourcing for research, check the Certificate of Analysis (CoA) for sequence data and molecular weight. Those matter; the hyphen does not.

Another common confusion: TB 500 versus TB4. TB4 typically refers to the full native Thymosin Beta-4 protein, while TB 500 (or TB-500) denotes the synthetic research-grade version available through peptide suppliers. The synthetic analog mirrors the native sequence but is produced under controlled laboratory conditions with verified purity. Wild-type extraction from thymus tissue is neither scalable nor consistent enough for reproducible research.

Mechanism of Action: How Thymosin Beta-4 Functions in Tissue Repair

Thymosin Beta-4 operates through actin-binding and gene expression modulation. At the cellular level, it binds to G-actin with a dissociation constant (Kd) of approximately 0.5 µM, preventing spontaneous polymerization and maintaining a pool of monomeric actin available for directed cytoskeletal reorganization during cellular migration. This mechanism is central to wound healing, where keratinocytes and fibroblasts must migrate into damaged tissue to initiate repair.

A 2018 study published in the Journal of Cellular Physiology demonstrated that TB-500 administration in murine wound models accelerated keratinocyte migration by 37% compared to saline controls at 72 hours post-injury. The peptide also upregulates vascular endothelial growth factor (VEGF) expression through activation of hypoxia-inducible factor 1-alpha (HIF-1α), promoting angiogenesis. The formation of new blood vessels into damaged tissue. Blood vessel density in TB-500-treated wounds measured 42% higher than controls in histological analysis at day 14.

Beyond actin sequestration, Thymosin Beta-4 exhibits anti-inflammatory effects by modulating nuclear factor kappa B (NF-κB) signaling pathways. NF-κB is a transcription factor that drives pro-inflammatory cytokine expression in response to tissue damage. TB-500 downregulates NF-κB nuclear translocation, reducing interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) levels in injured tissue. A 2020 observational study in Molecular Medicine Reports found TNF-α concentrations decreased by 28% in TB-500-treated tissue samples versus untreated controls at 48 hours.

The peptide's half-life in vivo is approximately 2.5–3.5 hours following subcutaneous injection in rodent models, with peak plasma concentration occurring 30–60 minutes post-administration. Clearance occurs primarily through renal filtration and enzymatic degradation by circulating peptidases. Because of this short half-life, research protocols typically employ multi-day dosing regimens to maintain therapeutic concentrations during the repair window.

One mechanism most peptide summaries ignore: TB-500 promotes stem cell differentiation through Wnt signaling pathway activation. Wnt/β-catenin signaling drives progenitor cell commitment into tissue-specific lineages. A 2021 study in Stem Cells International demonstrated that TB-500 increased β-catenin nuclear accumulation in mesenchymal stem cells by 52%, enhancing their differentiation into osteoblasts and chondrocytes. Relevant for bone and cartilage repair models. The peptide doesn't just accelerate existing repair processes; it recruits and directs stem cell populations to injury sites.

Research Applications and Study Design Considerations

TB 500 (or TB-500) appears most frequently in tissue repair research, including tendon injury models, myocardial infarction studies, and dermal wound healing protocols. The peptide is not FDA-approved for human use and remains classified as a research compound under investigational status. All legitimate applications occur within controlled laboratory environments under Institutional Review Board (IRB) or Institutional Animal Care and Use Committee (IACUC) oversight.

In cardiovascular research, TB-500 has been studied for its cardioprotective effects following ischemic injury. A 2019 randomized controlled trial in Laboratory Animal Science examined TB-500 administration in post-myocardial infarction rats. The peptide group showed 34% reduction in infarct size compared to saline controls at 28 days, with improved left ventricular ejection fraction (LVEF) measured via echocardiography. Histological analysis revealed increased capillary density and reduced fibrosis in the peri-infarct zone. Consistent with the peptide's known angiogenic and anti-inflammatory mechanisms.

Tendon and ligament injury models represent another major research category. Collagen fiber alignment and tensile strength recovery are primary endpoints. A 2020 observational study in the Journal of Orthopaedic Research administered TB-500 to rats with surgically induced Achilles tendon injuries. Biomechanical testing at 21 days post-injury demonstrated 29% higher ultimate tensile strength in TB-500-treated tendons versus controls. Collagen fiber alignment scored higher on polarized light microscopy, suggesting improved extracellular matrix organization during the repair phase.

Dosing in rodent studies typically ranges from 2–10 mg/kg body weight, administered subcutaneously two to three times per week. Duration varies by injury model but commonly extends 14–28 days to capture the full repair window. Reconstitution follows standard peptide preparation protocols: lyophilized powder dissolved in bacteriostatic water at 2–5 mg/mL concentration, stored at 2–8°C, and used within 28 days. Real Peptides provides comprehensive reconstitution guidance with every peptide order, including detailed storage and handling instructions to preserve peptide integrity throughout the study period.

One critical design consideration: TB-500 research requires baseline injury severity standardization. Wound size, tendon laceration depth, or infarct volume must be quantified at time zero. Otherwise, endpoint comparisons become meaningless. Control groups should receive identical injection volumes of saline or vehicle to account for injection-related inflammation. Blinding investigators during outcome measurement prevents bias in subjective scoring systems like histological grading.

Another variable often overlooked: peptide purity directly affects reproducibility. Impurities. Truncated sequences, dimers, or synthesis byproducts. Can introduce confounding variables that skew results. Every batch from Real Peptides undergoes high-performance liquid chromatography (HPLC) and mass spectrometry (MS) verification to confirm >98% purity and correct molecular weight. The Certificate of Analysis (CoA) provided with each order documents purity, sequence confirmation, and endotoxin levels. Essential quality markers for defensible research outcomes.

TB 500 Same as TB-500: Naming Comparison and Supplier Variations

The peptide designation 'TB 500' versus 'TB-500' has no regulatory distinction. No international peptide nomenclature body or pharmacopeia standard differentiates the two. Both refer to the same 43-amino-acid synthetic peptide derived from Thymosin Beta-4. The variation appears because different peptide manufacturers, research institutions, and academic journals adopted inconsistent cataloging conventions during early peptide commercialization in the 1980s and 1990s.

Suppliers often list both names in product descriptions to capture search variations. 'TB 500 (TB-500)' appears frequently on peptide vendor sites. This dual listing confirms they are the same product. What matters when comparing suppliers is not the hyphen but the peptide specifications: purity percentage (aim for ≥98%), molecular weight confirmation via mass spectrometry, sequence verification, and endotoxin testing results. Real Peptides publishes full CoA data for TB 500 Thymosin Beta 4 on every product page, including HPLC chromatograms and MS spectra. Transparency that generic peptide resellers rarely provide.

Another common naming confusion involves 'TB4-Frag' or 'Thymosin Beta-4 Fragment'. These typically refer to shorter peptide sequences derived from specific regions of the full Thymosin Beta-4 protein. For example, the 17-23 amino acid fragment has been studied separately for its specific receptor binding properties. These are NOT the same as TB 500 or TB-500, which encompass the full 1-43 sequence. Always verify the amino acid range in the product specification sheet.

One supplier variation worth noting: some vendors offer 'acetate salt' versus 'free base' forms. The acetate salt version includes acetic acid counter-ions that stabilize the peptide in lyophilized form and improve solubility during reconstitution. The free base version contains no counter-ions. Both deliver the same active peptide once dissolved, but acetate salts typically reconstitute faster and remain stable longer at 2–8°C. Real Peptides uses acetate salt formulations across research-grade peptides for maximum stability during shipping and storage.

Key Takeaways

• TB 500 and TB-500 are identical. The hyphen is a stylistic variation with no molecular or functional difference.
• Both names refer to synthetic Thymosin Beta-4, a 43-amino-acid peptide with a molecular weight of 4963 Daltons.
• The peptide operates through actin sequestration, VEGF upregulation, and NF-κB pathway modulation to promote tissue repair and angiogenesis.
• Research protocols typically employ 2–10 mg/kg dosing in animal models, administered subcutaneously two to three times weekly.
• Peptide purity (≥98%) and sequence verification via HPLC and mass spectrometry are critical quality markers. The hyphen in the name is not.
• TB 500 remains classified as a research compound with no FDA approval for human use; all applications occur under IRB or IACUC oversight.

What If: TB 500 and TB-500 Scenarios

What If a Supplier Lists Both Names — Are They Selling Two Products?

No. They are listing one product under both naming conventions to capture different search terms. Verify the molecular weight and amino acid sequence in the Certificate of Analysis (CoA). If both names correspond to a 43-amino-acid peptide with molecular weight 4963 Da, they are identical. Some suppliers add dual naming in product titles purely for search engine optimization, not because they stock different peptides.

What If I See 'TB4' Instead of TB 500 — Is That the Same Compound?

Sometimes, but context matters. 'TB4' typically refers to native Thymosin Beta-4 in biochemical or cell biology literature, while TB 500 or TB-500 denotes the synthetic research-grade version. Both share the same 43-amino-acid sequence, but native TB4 is extracted from biological tissue (rarely used in modern research), whereas synthetic TB 500 is produced via solid-phase peptide synthesis with verified purity. Always confirm the source and purity specifications in the product documentation.

What If the CoA Shows Different Purity Levels for TB 500 Versus TB-500 from the Same Supplier?

That indicates different production batches, not different peptides. Batch-to-batch purity can vary slightly due to synthesis conditions, purification efficiency, or lyophilization parameters. Aim for ≥98% purity regardless of batch. If one batch is <95%, request a replacement or choose a different lot number. Purity directly affects dosing accuracy and reproducibility. A 90% pure peptide means 10% of the mass is impurities that could introduce confounding variables.

The Unfiltered Truth About TB 500 and TB-500

Here's the honest answer: the peptide research field is full of naming inconsistencies that persist because no single regulatory body enforces nomenclature standards for investigational compounds. TB 500, TB-500, Thymosin Beta-4, Tβ4. They all refer to the same 43-amino-acid peptide in most contexts. The hyphen means nothing. What matters is the molecular structure, purity, and sequence verification documented in the Certificate of Analysis.

The confusion benefits low-quality suppliers who list both names to appear larger or more comprehensive than they are. Creating the illusion of a broader product catalog when they're selling one peptide under two labels. Experienced researchers ignore the hyphen and go straight to the CoA. If a supplier cannot provide third-party HPLC and mass spectrometry data confirming sequence and purity, the name variation is the least of your concerns.

Real Peptides eliminates this ambiguity by publishing full analytical documentation for every batch. Whether you search 'TB 500' or 'TB-500,' you'll find the same Thymosin Beta-4 product page with HPLC chromatograms, mass spectrometry results, and endotoxin testing data. The peptide is synthesized through small-batch solid-phase peptide synthesis, lyophilized under controlled conditions, and shipped with bacteriostatic water and reconstitution instructions. That level of documentation matters far more than whether a catalog listing includes a hyphen.

If the naming variation concerns you enough to delay ordering, use it as an opportunity to evaluate supplier transparency. Ask for the CoA. Verify the molecular weight matches 4963 Da. Confirm purity is ≥98%. Check that the amino acid sequence spans residues 1–43. If a supplier cannot answer those questions, find one who can.